Principal Financial Group Inc. Increases Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Principal Financial Group Inc. boosted its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 2.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 126,337 shares of the company's stock after purchasing an additional 2,884 shares during the period. Principal Financial Group Inc. owned approximately 0.44% of Krystal Biotech worth $22,779,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Teacher Retirement System of Texas lifted its stake in Krystal Biotech by 27.3% in the fourth quarter. Teacher Retirement System of Texas now owns 6,383 shares of the company's stock worth $1,000,000 after purchasing an additional 1,369 shares during the last quarter. Fifth Third Bancorp increased its position in shares of Krystal Biotech by 159.1% during the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after acquiring an additional 105 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Krystal Biotech during the fourth quarter worth approximately $15,989,000. JPMorgan Chase & Co. increased its position in shares of Krystal Biotech by 18.7% during the fourth quarter. JPMorgan Chase & Co. now owns 151,835 shares of the company's stock worth $23,786,000 after acquiring an additional 23,934 shares during the period. Finally, Federated Hermes Inc. increased its position in shares of Krystal Biotech by 1.8% during the fourth quarter. Federated Hermes Inc. now owns 13,048 shares of the company's stock worth $2,044,000 after acquiring an additional 229 shares during the period. Institutional investors own 86.29% of the company's stock.

Krystal Biotech Price Performance

NASDAQ KRYS traded down $1.57 during trading hours on Friday, hitting $148.17. 267,497 shares of the company's stock traded hands, compared to its average volume of 287,362. Krystal Biotech, Inc. has a 52-week low of $122.80 and a 52-week high of $219.34. The company has a market capitalization of $4.28 billion, a PE ratio of 35.62 and a beta of 0.67. The firm's 50-day moving average is $135.82 and its 200-day moving average is $156.26.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. The business had revenue of $88.18 million for the quarter, compared to analysts' expectations of $98.66 million. Equities research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

KRYS has been the topic of a number of research reports. HC Wainwright reaffirmed a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a research report on Tuesday, June 24th. Chardan Capital reaffirmed a "buy" rating and set a $219.00 target price on shares of Krystal Biotech in a research report on Wednesday, May 7th. Guggenheim reduced their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Citigroup reaffirmed a "neutral" rating and set a $176.00 target price (up from $155.00) on shares of Krystal Biotech in a research report on Wednesday. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Krystal Biotech has an average rating of "Buy" and an average target price of $213.75.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 6,927 shares of the business's stock in a transaction dated Thursday, July 10th. The shares were sold at an average price of $150.27, for a total value of $1,040,920.29. Following the transaction, the insider directly owned 1,525,929 shares in the company, valued at $229,301,350.83. The trade was a 0.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last quarter, insiders have sold 13,927 shares of company stock valued at $2,092,852. Insiders own 13.70% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).